BMRN:NASDAQ
Biomarin Pharmaceutical Inc
$55.20
arrow_downward
-1.81%(-1.02) 1D
Oct 7, 12:59:30 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMRN...
Open
$56.05
High
$56.60
Low
$55.17
Mkt. cap
10.69B
Avg. vol.
2.01M
Volume
678.39K
P/E ratio
148.82
52-wk high
$70.98
52-wk low
$49.26
EPS
$0.37
Beta
0.22
Shares outstanding
193.57M
No. of employees
3K
Open
$56.05
High
$56.60
Low
$55.17
Mkt. cap
10.69B
Avg. vol.
2.01M
Volume
678.39K
P/E ratio
148.82
52-wk high
$70.98
52-wk low
$49.26
EPS
$0.37
Beta
0.22
Shares outstanding
193.57M
No. of employees
3K
News stories
From web sources and news partners
Zacks
·
1 hour ago
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
AD HOC NEWS
·
14 hours ago
BioMarin flags USD 283 million charge. BioMarin stock loses 1.83 percent.
TradingView
·
18 hours ago
BioMarin Q3 financial results to see IPR&D expense impact of $283M
PR Newswire
·
1 day ago
BioMarin Appoints Cara Bauer as Chief People Officer
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3.22K
FoundedMar 1997
HeadquartersSan Rafael, California, United States
SectorBiotechnology
Websitebiomarin.com